<DOC>
	<DOCNO>NCT01009242</DOCNO>
	<brief_summary>The primary objective determine relationship blood level CDP6038 suppression C-reactive Protein ( CRP ) follow single dos give intravenous ( IV ) infusion subcutaneous ( SC ) injection Rheumatoid Arthritis ( RA ) patient . The safety CDP6038 also evaluate .</brief_summary>
	<brief_title>To Evaluate Blood Levels Safety IV Subcutaneous CDP6038 Subjects With Rheumatoid Arthritis Using Methotrexate</brief_title>
	<detailed_description>The secondary objective study include determination absolute bioavailability CDP6038 give via sc administration compare iv infusion ; assessment immunogenicity potential single dose CDP6038 assessment , exploratory basis , relevant systemic biomarkers change clinical response .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>RA &gt; 6 month duration stable Methotrexate ≤9 swell ≤9 tender joint ( 28 joint count ) Minimum Screening CRP 0.5mg/L Participation previous study define agent duration Previous treatment define agent duration Presence , history define medical condition include particularly associate deficiency immune response Pregnancy Positive tests/signs possible latent/active tuberculosis Positive HIV Drug addiction alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>CDP6038</keyword>
</DOC>